Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Saved in:
| Title: | Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study. |
|---|---|
| Authors: | Weiden PJ; Alkermes, Inc., Waltham, MA, USA. pjweiden@gmail.com.; Karuna Therapeutics, 33 Arch Street, Suite 3110, Boston, MA, 02110, USA. pjweiden@gmail.com., Du Y; Alkermes, Inc., Waltham, MA, USA., von Moltke L; Alkermes, Inc., Waltham, MA, USA., Wehr A; Alkermes, Inc., Waltham, MA, USA., Hard M; Alkermes, Inc., Waltham, MA, USA.; Moderna, Inc., Cambridge, MA, USA., Marandi M; Radiant Clinical Research, Cerritos, CA, USA., Walling DP; CNS Network, LLC, Garden Grove, CA, USA. |
| Source: | CNS drugs [CNS Drugs] 2020 Sep; Vol. 34 (9), pp. 961-972. |
| Publication Type: | Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9431220 Publication Model: Print Cited Medium: Internet ISSN: 1179-1934 (Electronic) Linking ISSN: 11727047 NLM ISO Abbreviation: CNS Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1179-1934 |
|---|---|
| DOI: | 10.1007/s40263-020-00745-1 |
